美股A股
StockGist

IQVIA Holdings Inc.

IQVNYSE · Healthcare · Medical - Diagnostics & Research
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Afr…
$265.12-2.21%
报价 2026-11-13
市值
$43.69B
EV
$58.58B
PE (TTM)
33.1x
预期 PE (FY2026)
20.5x
52 周区间距高点 -5.1%
$156.66$279.36

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

爆发潜力

2026-11-13
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-121.1x12.81 → 14.16(1.1x)18.7
FY+32028-121.1x12.81 → 15.91(1.2x)16.7

毛利率 26% · TTM 收入 $17311M · 基数 EPS 12.81(调整后)

电话会信号

辅助标签
Q3 20262026-10-27
需求加速AI 词频高积压订单词频高上调指引
指引 上调
信心 5
分析师 4

“Last 12-month net new bookings up 14% year over year, increasing for 5 consecutive quarters, supporting long-term growth.”

原文引用(2)
  • 需求加速:our last 12-month net new bookings have now increased for 5 consecutive quarters.
  • 上调指引:We are raising our full year 2026 guidance for revenue for adjusted EBITDA, and for adjusted diluted earnings per share.

蓝色标签在暴涨研究中略有区分度;悬停查看口径。

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
IQVIQVIA Holdings Inc.$43.69B-2.2%+8.0%32.9%33.1x16.6x16.9x
CAHCardinal Health, Inc.$64.97B+1.1%+4.1%4.3%31.6x16.9x11.9x
HUMHumana Inc.$54.05B+1.4%+26.1%11.7%43.0x18.3x71.8x
AAgilent Technologies, Inc.$49.05B+0.5%+6.5%26%27.1x23.0x34.2x
WATWaters Corporation$45.24B-0.4%+105.3%58.9%28.0x18.3x155.1x高增长
HLNHaleon plc$40.25B+0.9%–61.8%21.8x14.3x–
GEHCGE HealthCare Technologies Inc.$37.54B+1.4%+6.5%40.3%21.8x14.2x31.5x
ALCAlcon Inc.$35.61B+3.2%–54.8%37.0x21.0x–
MTDMettler-Toledo International Inc.$34.59B+0.5%+6.6%57.5%29.1x22.2x39.7x
同行中位数––+6.6%47.6%28.5x18.3x36.9x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
2024-09-30
Q3 2024
Revenue$4.37B$4.15B$4.36B$4.1B$4.02B$3.83B$3.96B$3.9B
Gross Margin32.9%32.6%6.7%33.5%32.9%33.9%34.8%35.4%
Operating Margin11.6%12.4%16.8%13.5%12.6%13%15.8%14.1%
Net Income$256M$274M$514M$331M$266M$249M$437M$285M
Diluted EPS1.531.612.991.931.541.42.421.55
Operating Cash Flow$558M$618M$735M$908M$443M$568M$885M$721M

研究材料